Search

Background of the Study: The increase in the therapeutic use of tramadol in the management of moderate to severe pains in some disease conditions and its unregulated access has led to its associated toxicity and there is little or no information on the protection against its associated toxicity. Aim of the Study: Considering the medicinal value of pumpkin seed oil, its availability, and neglected use, it becomes necessary to evaluate the possible potential of the seed oil in tramadol-induced oxidative stress in Wister Albino rats. Methods of the Study: This study used fifty-six (56) albino rats to determine the impact of Cucurbita pepo seed oil (CPSO) on tramadol-induced oxidative stress. The rats were grouped into 7. After a week of acclimatization, rats in group 1 (normal control) had access to water and food, while rats in group 2 received 5 mL/Kg (b.w) of normal saline. 100 mg/kg of tramadol (TM) was delivered to groups 3–6 to induce toxicity. The third group (TM control) received no treatment, whilst the other 3 groups (TM-CPSO treatment groups) received 5, 2.5, and 1.5 mL/Kg of CPSO, respectively. Group 7 received only 5 mL/kg CPSO (CPSO group). Similarly, groups 2 through 7 had unrestricted access to food and water for 42 days and received treatments via oral intubation once per day. Indicators of oxidative stress were discovered in the brain homogenate. Results: TM toxicity was demonstrated by a considerable increase (P <.05) in the brain MDA level and a significant drop (P <.05) in the brain GSH level, as well as a significant reduction (P <.05) in GPx, catalase, SOD, GST, and quinone reductase activities. Conclusion: The dose-dependent delivery of CPSO was able to restore not only the activity but also the concentrations of the altered markers. [ABSTRACT FROM AUTHOR]

Several studies revealed that different parts of Azadirachta indica A. Juss, has therapeutic potential against inflammatory issues and dyslipidemia which is a major contributing cause to cardiovascular diseases, oxidative stress and serum glucose levels, etc. Present study was conducted to evaluate anti-dyslipidemic capacity of Azadirachta indica leaf extract in dyslipidemic rabbits. Ethanolic extract of Azadirachta indica leaves was obtained by using Soxhlet apparatus. This extract was used for efficacy study on rabbits. In this context, 25 healthy rabbits were selected for study, Efficacy trial involved five groups of rabbits, 5 rabbits in each group; NC (Negative Control); healthy rabbits received normal diet. In remaining 20 rabbits, dyslipidemia was induced by using high fat diet for 28 days followed by administration of Azadirachta indica leaf ethanolic extract for 60 days in a dose-dependent manner. PC (Positive Control) include dyslipidemic rabbits received normal diet while G 1 , G 2 , G 3 groups included dyslipidemic rabbits receiving different concentrations of Azadirachta indica leaf extract (i.e. 300, 500 and 700 mg/kg of body weight, respectively). Blood samples were analyzed for serum lipid profile after every 15 days to determine the effect of treatments. Significant reduction in total cholesterol (60 ± 3.4 mg/dL), triglycerides (40.31 ± 2.5 mg/dL) and low-density lipoprotein (28.87 ± 2.1 mg/dL) was observed in G 2 (P ≤ 0.05)while a significant increase was observed in high-density lipoprotein (60.47 ± 1.7 mg/dL) of G 2 (P ≤ 0.05) as compared to other groups. Results revealed that ethanolic extract of Azadirachta indica leaves in G 2 group (@ 500 mg/kg of body weight) normalized lipid profile in dyslipidemic rabbits after 60 days of extract administration which significantly lowered TC, TG, LDL levels (P ≤ 0.05) and improved HDL level. [Display omitted] [ABSTRACT FROM AUTHOR]

Abstract: The study was undertaken to determine the efficacy of hydro-methanolic (1:1) extract of tamarind (Tamarindus indica L.) fruit pulp in removing body fluoride burden. Thirty rats were divided into five groups. Keeping no fluoride group as the control, rats of no treatment, low dose, middle dose and high dose groups received sodium fluoride orally at the rate of 200mg per kg body weight daily for 14weeks. Rats of low dose, middle dose and high dose group simultaneously received tamarind fruit pulp extract at three doses, viz. 25 (low), 50 (medium) and 100mg (high) per kg body weight orally, respectively. Fluoride concentration in blood, urine and long bone of experimental rats was monitored to assess the efficacy of the extract. Mean serum fluoride concentration in fluoride exposed rats was 0.145±0.009 and 0.783±0.042μg/ml on days 0 and 98. In comparison, fluoride concentrations in tamarind treated rats were 0.179±0.021 and 0.633±0.015; 0.179±0.021 and 0.502±0.025 and 0.176±0.021 and 0.498±0.030μg/ml in low, medium and high dose groups, respectively on day 0 and day 98 of the experiment. There was a significant (p ⩽0.01) increase in urinary fluoride excretion from day 28 onwards. The mean fluoride concentration in long bones of treated rats was significantly lower than the values recorded in fluoride exposed rats. These findings suggest that concomitant use of tamarind fruit pulp extract can reduce fluoride concentration in blood and bone and enhanced urinary excretion, indicating the ameliorative potential of fruits of tamarind in fluoride toxicity. [Copyright &y& Elsevier]

The prophylactic efficacy of arjuna ( Terminalia arjuna L.) extract to reduce tissue lead (-Pb) concentration was evaluated experimentally in rats. Thirty female rats were divided into five groups, with group A as the control. Rats of groups B, C, D, and E received lead acetate orally at the rate of 5 mg per kg body weight daily for 6 weeks. The arjuna extract was tried in three doses, viz., 50 mg (low), 100 mg (medium), and 200 mg (high) per kg body weight orally and given simultaneously with Pb salt to the rats of groups C, D, and E, respectively. Mean blood Pb concentration in Pb-exposed rats ranged between 0.13 ± 0.02 and 0.96 ± 0.06 µg/ml, whereas in arjuna-treated rats, the range was between 0.15 ± 0.02 and 0.94 ± 0.06, 0.17 ± 0.01 and 0.77 ± 0.06, and 0.13 ± 0.1 and 0.51 ± 0.07 µg/ml in low-, medium-, and high-dose groups, respectively. The mean Pb concentration in liver, kidneys, brain, and bone of Pb-exposed rats was 2.289 ± 0.206, 4.748 ± 0.609, 1.019 ± 0.10, and 44.075 ± 2.60 µg/g, respectively. Concomitant use of arjuna bark extract at three different doses was found to reduce Pb concentration considerably in these vital organs indicating the potential therapeutic activity of arjuna against lead toxicity. [ABSTRACT FROM AUTHOR]